Transgene SA (FR:TNG)
:TNG
Want to see FR:TNG full AI Analyst Report?
TNG Stock Chart & Stats
€0.94
<€0.01(0.40%)
At close: 4:00 PM EST
€0.94
<€0.01(0.40%)
Day’s Range― - ―
52-Week Range€0.53 - €1.50
Previous CloseN/A
Volume15.92K
Average Volume (3M)129.86K
Market Cap
€231.51M
Enterprise Value€115.81M
Total Cash (Recent Filing)€111.86M
Total Debt (Recent Filing)€2.06M
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding277,532,530
10 Day Avg. Volume204,663
30 Day Avg. Volume129,863
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)1.14
Price to Sales (P/S)1011.31
P/FCF Ratio-3.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€9.01M
Bulls Say, Bears Say
Bulls Say
Strengthened Funding RunwayThe EUR105M raise plus EUR39M debt conversion materially extends runway to early 2028, reducing near-term refinancing risk and allowing management to fund trials and manufacturing investments. This creates a multi-quarter window to achieve clinical de-risking and partnership milestones before new capital is required.
Compelling Phase I Clinical Signals For TG4050Durable Phase I efficacy (100% DFS in treated cohort) and reported neoantigen-specific T cell responses create structural value beyond a single readout: they substantiate the platform's mechanism, improve the odds of successful randomized endpoints, and materially enhance partnering and licensing appeal over the medium term.
Very Low Financial LeverageMinimal debt and a sizable equity base give Transgene financial flexibility to invest in R&D and manufacturing without heavy interest burdens. Low leverage lowers solvency risk and preserves strategic optionality for partnerships or asset-light deal structures over the next several quarters.
Bears Say
Consistent Negative Cash Flow And High BurnSustained negative operating and free cash flow shows the business consumes capital to fund trials and manufacturing. Even with current runway, ongoing annual burn near ~EUR38M implies recurring financing needs or dilution risk if clinical or partnering milestones slip, pressuring long-term funding sustainability.
Severely Reduced Revenue And Persistent LossesA near-total collapse in product or service revenue and sustained large negative margins mean Transgene cannot self-fund operations from commercial receipts. This structural lack of recurrent revenue increases dependency on milestone/partner funding and heightens vulnerability to capital-market conditions over the medium term.
Manufacturing And Execution Timing RiskTargeting full GMP capacity only by Q3 2027 creates a multi-year operational bottleneck: it can delay pivotal trial starts, limit scale-up for registrational studies, and slow partner-led commercialization. Execution delays would materially affect timeline-driven value creation and could force additional funding rounds or partner concessions.
Transgene News
TNG FAQ
What was Transgene SA’s price range in the past 12 months?
Transgene SA lowest stock price was €0.53 and its highest was €1.50 in the past 12 months.
What is Transgene SA’s market cap?
Transgene SA’s market cap is €231.51M.
When is Transgene SA’s upcoming earnings report date?
Transgene SA’s upcoming earnings report date is Sep 24, 2026 which is in 126 days.
How were Transgene SA’s earnings last quarter?
Currently, no data Available
Is Transgene SA overvalued?
According to Wall Street analysts Transgene SA’s price is currently Overvalued.
Does Transgene SA pay dividends?
Transgene SA does not currently pay dividends.
What is Transgene SA’s EPS estimate?
Transgene SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Transgene SA have?
Transgene SA has 277,532,530 shares outstanding.
What happened to Transgene SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Transgene SA?
Currently, no hedge funds are holding shares in FR:TNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
OSE Immunotherapeutics SA
―
Cellectis SA
―
MaaT Pharma
―